Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Financings
Financings
| Raise | Date |
|---|---|
| Warrant exercise of shares of common stock on exercise of existing warrants, with new unregistered warrants Tranche closed: US$11.5M raised · US$2.05 a share · Warrants at US$2.05 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and, primarily, accelerated development activities for the next clinical phase of PH-762 for cutaneous carcinomas | Nov 13, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Closed: US$1.83M raised · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes, including the Phase 1b trial of PH-762 and development of PH-894 | Jan 21, 2025 |
| Warrant exercise of warrants issued July 12, 2024 Closed: US$2.9M raised · US$5.45 a share | Jan 21, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: US$2.5M · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Jan 15, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: US$3.19M · US$3 a share · Warrants at US$3 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Jan 14, 2025 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: US$480,000 · US$2 a share · Warrants at US$2 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Dec 23, 2024 |
| Registered direct offering of common stock with concurrent private placement warrants Announced: about US$1.15M · US$2.635 a share · Warrants at US$2.51 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Dec 19, 2024 |